Conformationally constrained compounds as pharmaceutical agents

Abstract

Novel substituted amino acids of formula are disclosed and are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, and neuropathological disorders. Processes for the preparation and intermediates useful in the preparation are also disclosed.

1 . A compound of formula  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof or a prodrug thereof wherein 
 R 1  to R 10  are each independently selected from hydrogen or a straight or branched alkyl of from 1 to 6 carbons, benzyl, or phenyl;  
 m is an integer of from 0 to 3;  
 n is an integer of from 1 to 2;  
 o is an integer of from 0 to 3;  
 p is an integer of from 1 to 2;  
 q is an integer of from 0 to 2;  
 r is an integer of from 1 to 2;  
 s is an integer of from 1 to 3;  
 t is an integer of from 0 to 2; and  
 u is an integer of from 0 to 1.  
 
     
     
         2 . A compound according to  claim 1  of Formula I.  
     
     
         3 . A compound according to  claim 1  of Formula I wherein 
 R 1  to R 10  is hydrogen;  
 m is of from 0 to 3; and  
 n is 1 or 2.  
 
     
     
         4 . A compound according to  claim 1  selected from: 
 (±)-2-Aza-spiro[3.5]nonane-1-carboxylic acid hydrochloride;  
 (±)-2-Aza-spiro[4.5]decane-4-carboxylic acid hydrochloride;  
 (R)-2-Aza-spiro[4.5]decane-4-carboxylic acid hydrochloride;  
 (S)-2-Aza-spiro[4.5]decane-4-carboxylic acid hydrochloride; and  
 (R)-2-Aza-spiro[4.5]decane-4-carboxylic acid.  
 
     
     
         5 . A compound according to  claim 1  of Formula II.  
     
     
         6 . A compound according to  claim 1  of Formula II wherein 
 R 1  to R 10  is hydrogen,  
 o is from 0 to 3; and  
 p is 1 to 2.  
 
     
     
         7 . A compound according to  claim 1  of Formula III wherein 
 R 1  to R 10  is hydrogen,  
 q is from 0 to 2; and  
 r is 1 to 2.  
 
     
     
         8 . A compound according to  claim 1  of Formula III wherein: 
 (±)-[3aS-(3α7aα)]-(Octahydro-isoindol-3a-yl)-acetic acid trifluoroacetate.  
 
     
     
         9 . A compound according to  claim 1  and selected from: 
 7-Methyl-2-aza-spiro[4.4]nonane-4-carboxylic acid;  
 [4α,5β(R*)]7-Methyl-2-aza-spiro[4.5]decane-4-carboxylic acid;  
 [4α,5α(S*)]7-Methyl-2-aza-spiro[4.5]decane-4-carboxylic acid;  
 [4α,5α(R*)]7-Methyl-2-aza-spiro[4.5]decane-4-carboxylic acid;  
 [4α,5β(S*)]7-Methyl-2-aza-spiro[4.5]decane-4-carboxylic acid;  
 7,8-Dimethyl-2-aza-spiro[4.4]nonane-4-carboxylic acid;  
 7-Methyl-2-aza-spiro[4.5]decane-4-carboxylic acid;  
 7,9-Dimethyl-2-aza-spiro[4.5]decane-4-carboxylic acid;  
 Spiro[bicyclo[3.3.1]nonane-9,3′-pyrrolidine]-4′-carboxylic acid;  
 Spiro[pyrrolidine-3,2′-tricyclo[3.3.1.1 3,7 ]decane]-4-carboxylic acid;  
 3-Amino-6-methyl-spiro[3.5]nonane-1-carboxylic acid;  
 3-Amino-6,8-dimethyl-spiro[3.5]nonane-1-carboxylic acid;  
 4-Amino-7-methyl-spiro[4.5]decane-1-carboxylic acid;  
 4-Amino-7,9-dimethyl-spiro[4.5]decane-1-carboxylic acid;  
 3-Amino-6-methyl-spiro[3.4]octane-1-carboxylic acid;  
 3-Amino-6,7-dimethyl-spiro[3.4]octane-1-carboxylic acid;  
 4-Amino-7-methyl-spiro[4.4]nonane-1-carboxylic acid; and  
 4-Amino-7,8-dimethyl-spiro[4.4]nonane-1-carboxylic acid.  
 
     
     
         10 . A pharmaceutical composition comprising a therapeutically effective amount of a compound according to  claim 1  and a pharmaceutically acceptable carrier.  
     
     
         11 . A method for treating epilepsy comprising administering a therapeutically effective amount of a compound according to  claim 1  to a mammal in need of said treatment.  
     
     
         12 . A method for treating faintness attacks, hypokinesia, and cranial disorders comprising administering a therapeutically effective amount of a compound according to  claim 1  to a mammal in need of said treatment.  
     
     
         13 . A method for treating neurodegenerative disorders comprising administering a therapeutically effective amount of a compound according to  claim 1  to a mammal in need of said treatment.  
     
     
         14 . A method for treating depression comprising administering a therapeutically effective amount of a compound according to  claim 1  to a mammal in need of said treatment.  
     
     
         15 . A method for treating anxiety comprising administering a therapeutically effective amount of a compound according to  claim 1  to a mammal in need of said treatment.  
     
     
         16 . A method for treating panic comprising administering a therapeutically effective amount of a compound according to  claim 1  to a mammal in need of said treatment.  
     
     
         17 . A method for treating pain comprising administering a therapeutically effective amount of a compound according to  claim 1  to a mammal in need of said treatment.  
     
     
         18 . A method for treating neuropathological disorders comprising administering a therapeutically effective amount of a compound according to  claim 1  to a mammal in need of said treatment.  
     
     
         19 . A compound selected from: 
 2-Benzyl-2-aza-spiro[4.5]decane-4,4-dicarboxylic acid dimethyl ester hydrochloride;    2-Aza-spiro[4.5]decane-4,4-dicarboxylic acid dimethyl ester hydrochloride;    1-Benzyloxymethyl-2-aza-spiro[3.5]nonane-2-carboxylic acid tert-butyl ester;    1-Hydroxymethyl-2-aza-spiro[3.5]nonane-2-carboxylic acid tert-butyl ester;    2-Aza-spiro[3.5]nonane-1,2-dicarboxylic acid 2-tert-butyl ester;    [3 aS-(3α7aα)]-7a-tert-Butoxycarbonylmethyl-1-oxo-octahydro-isoindole-2-carboxylic acid tert-butyl ester; and    [3aS-(α7aα)]-3a-tert-Butoxycarbonylmethyl-octahydro-isoindole-2-carboxylic acid tert-butyl ester.